Ann: ResApp receives Advanced and Overseas R&D Finding, page-3

ResApp receives Advanced and Overseas R&D finding.
14 September 2021 – ResApp Health Limited (ASX:RAP), a leading digital
health company developing smartphone applications for the diagnosis and management of
respiratory disease is pleased to announce that it has received approval from AusIndustry for its
application for an Advanced and Overseas Finding in respect to expenditure associated with its
COVID-19 clinical studies.
The finding covers financial years 2021, 2022 and 2023 and means that eligible overseas research
and development expenditure in ResApp’s COVID-19 clinical studies, in additional to Australian
expenditure, will be subject to a 43.5% cash rebate under the Australian Federal Government’s
R&D Tax Incentive Program. The company now estimates that it will receive an R&D rebate of
approximately $820,000 for the financial year ended 30 June 2021.